Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia - Summary - MDSpire

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • By

  • Yuto Sunaga

  • Yohei Hasebe

  • Masashi Yoshizawa

  • Yosuke Kono

  • Keiichi Koizumi

  • Nobuyuki Katsumata

  • Takako Toda

  • Minako Hoshiai

  • Koji Kobayashi

  • Sho Hokibara

  • Hiroko Oshiro

  • Emi Sawanobori

  • Tomoaki Sano

  • Masanori Ohta

  • Makoto Tsuruta

  • Makoto Nakamura

  • Kazumasa Sato

  • Hiroki Sato

  • Takeshi Inukai

  • June 4, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of infliximab as a second-line treatment for Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) and to identify specific clinical subgroups suitable for either infliximab or additional IVIG.

Approach:
    Key Findings:
    • Time to fever resolution was significantly shorter in the infliximab group compared to the additional IVIG group.
    • Clustering analysis identified laboratory factors, including serum sodium, CRP, total and HDL cholesterol, that correlated with responses to second-line therapies.
    Interpretation:

    The study suggests infliximab may be more effective than additional IVIG for treating IVIG-resistant KD, but further research is needed to refine subgroup identification for treatment selection.

    Limitations:
    • The study was retrospective and may have biases associated with observational data, which could affect the reliability of the findings.
    • The clustering approach may not fully capture all relevant clinical variables influencing treatment response.
    Conclusion:

    Infliximab appears to be a promising second-line treatment for IVIG-resistant Kawasaki disease, with potential for tailored therapy based on clinical subgroups.

Original Source(s)

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • by Yuto Sunaga, Yohei Hasebe, Masashi Yoshizawa, Yosuke Kono, Keiichi Koizumi, Nobuyuki Katsumata, Takako Toda, Minako Hoshiai, Koji Kobayashi, Sho Hokibara, Hiroko Oshiro, Emi Sawanobori, Tomoaki Sano, Masanori Ohta, Makoto Tsuruta, Makoto Nakamura, Kazumasa Sato, Hiroki Sato, Takeshi Inukai

  • June 4, 2026

Related Content

A case report of a rare and distinctive pacing pattern during left bundle branch pacing in a child with third-degree atrioventricular block following ventricular septal defect repair

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child